According to GlobalData’s medical device pipeline database, 57 Vascular Grafts devices are in various stages of development globally. GlobalData’s report Vascular Grafts provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 34 are in active development, while the remaining 24 are in an inactive stage of development. There are 22 products in the early stages of development, and the remaining 12 are in the late stages of development.
Vascular grafts are tubes made up of natural tissue or synthetic materials surgically implanted in the veins and arteries. Vascular Grafts are the implants used to repair, bypass or replace sections of blood vessels during surgical procedures. They are also used to patch injured or diseased areas in the arteries and for the replacement of whole segments of larger arteries such as the aorta. Vascular grafts are classified into autografts, allografts and synthetic vascular grafts on the basis of the materials. Autograft vascular grafts are vascular grafts taken from the individual and used in the same individual. These grafts are not tracked in this market. Allograft vascular grafts are vascular grafts taken from another individual and used in the treated patient. Synthetic vascular grafts are the grafts which are manufactured using polymers. Polyester and Polytetrafluoroethylene (PTFE) are the two synthetic materials used to construct synthetic vascular grafts. Synthetic (polyethylene terephthalate) vascular grafts are made from polymer yarn woven tubes whereas Synthetic PTFE vascular grafts are made by mechanically stretching sheets of polytetrafluoroethylene. One unit refers to one vascular graft.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Vascular Grafts pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Vascular Grafts devices. Overall, most of these Vascular Grafts pipeline devices are being developed by private entities.
Key players involved in the active development of Vascular Grafts include Humacyte, RUA Vascular, 3DT Holdings, Eqalix, FIT Biotech, Cytograft Tissue Engineering, DSM Biomedical, Gel-Del Technologies, Hannover Medical School and Andes University.
For a complete picture of the developmental pipeline for Vascular Grafts devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
